tacrolimus

(redirected from Advagraf)
Also found in: Medical.

ta·cro·li·mus

 (tə-krō′lə-məs)
n.
An immunosuppressive drug produced by the actinomycete Streptomyces tsukubaensis, C44H69NO12, used in combination with corticosteroids to prevent rejection of organ transplants.

[t(sukubaensis), specific epithet (after Mount Tsukuba, Japan, near which the actinomycete was discovered) + (m)acrol(ide) im(m)u(no)s(uppressant).]
Translations

tacrolimus

n tacrolimus m, tacrolimús m (INN)
Mentioned in ?
References in periodicals archive ?
Prior information notice without call for competition:(advagraf) tacrolimus 1 mg capsula liberation modified
Immunosuppressive therapy before and after RALP N = 12 Before RALP After RALP A: Calcineurin inhibitors 11/12 * (91.7%) 7/12 (58.3%) (Prograf, Advagraf) B: Corticosteroids 5/12 (41.7%) 4/12 (33.3%) C: Antimetabolite 10/12 (83.3%) 6/12 (50%) (Cellcept) D: mTor inhibitors 0/12 (0%) 8/12 * (66.7%) (Rapamune, Certican) RALP: robot-assisted laparoscopic radical prostatectomy; mTOR: mammalian target of rapamycin.
In US tests, Advagraf boosted survival of transplanted livers by 8% compared with patients treated with twice-daily Tacrolimus which costs PS1.23 a time.
Although sales in the Americas were down 6%, sales in Europe were up 24%, and the once-daily formulation Advagraf, was up 35%, while Asia and Oceania and Japan sales were up 32% and 2%, respectively.
Astellas was granted marketing approval for tacrolimus extended release capsules under the trade name Advagraf in Europe in 2007 and under the trade name Graceptor in Japan in 2008.
Astellas markets tacrolimus extended release capsules under the trade name Advagraf in Europe, and as Graceptor in Japan.
Advagraf is a once-daily modified release formulation of Astellas' Prograf(R) (tacrolimus, twice-daily formulation) for prevention of transplant rejection in kidney or liver recipients.
M2 PHARMA-October 24, 2011-EMA approves recall of Advagraf 0.5 mg capsules(C)2011 M2 COMMUNICATIONS